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Abstract
Background: Health state utility values (HSUVs) are essential parameters in model-based economic evaluations. This
study systematically identifies HSUVs in head and neck cancer and provides guidance for selecting them from a
growing body of health-related quality of life studies.
Methods: We systematically reviewed the published literature by searching PubMed, EMBASE and The Cochrane
Library using a pre-defined combination of keywords. The Tufts Cost-Effectiveness Analysis Registry and the School
of Health and Related Research Health Utilities Database (ScHARRHUD) specifically containing health utilities were
also queried, in addition to the Health Economics Research Centre database of mapping studies. Studies were
considered for inclusion if reporting original HSUVs assessed using established techniques. The characteristics of
each study including country, design, sample size, cancer subsite addressed and demographics of responders were
summarized narratively using a data extraction form. Quality scoring and critical appraisal of the included studies
were performed based on published recommendations.
Results: Of a total 1048 records identified by the search, 28 studies qualified for data extraction and 346 unique
HSUVs were retrieved from them. HSUVs were estimated using direct methods (e.g. standard gamble; n = 10 studies),
multi-attribute utility instruments (MAUIs; n = 13) and mapping techniques (n = 3); two studies adopted both direct and
indirect approaches. Within the MAUIs, the EuroQol 5-dimension questionnaire (EQ-5D) was the most frequently used
(n = 11), followed by the Health Utility Index Mark 3 (HUI3; n = 2), the 15D (n = 2) and the Short Form-Six Dimension
(SF-6D; n = 1). Different methods and types of responders (i.e. patients, healthy subjects, clinical experts) influenced the
magnitude of HSUVs for comparable health states. Only one mapping study developed an original algorithm using
head and neck cancer data. The identified studies were considered of intermediate quality.
Discussion: This review provides a dataset of HSUVs systematically retrieved from published studies in head and neck
cancer. There is currently a lack of research for some disease phases including recurrent and metastatic cancer, and
treatment-related complications. In selecting HSUVs for cost-effectiveness modeling purposes, preference should be
given to EQ-5D utility values; however, mapping to EQ-5D is a potentially valuable technique that should be further
developed in this cancer population.
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Background
Cost-utility models are increasingly used to establish
whether the cost of a new treatment is justified in terms
of health gains. This approach usually adopts the
quality-adjusted life year (QALY) as a measure of health
effectiveness. According to Neumann et al., the QALY
corresponds to the time spent in a series of quality-
weighted health states, where the weights represent the
desirability of living in that state [1]. The basic idea is
that individuals move through health states over time
and that each health state has a preference weight at-
tached to it [2], also known as a health state utility value
(HSUV). Thus, the HSUV can be interpreted as the
strength of preference for a given health state on a car-
dinal scale anchored at 0 (‘death’) and 1 (‘full health’),
with some instruments also allowing for negative values
representing states worse than death [3]. Therefore,
QALYs are obtained by summing-up the products of the
time spent in each health state and its corresponding
preference-based value [4].
HSUVs can be estimated in a variety of ways including
direct methods, multi-attribute utility instruments
(MAUIs), mapping functions and expert opinion. The
most common ways of eliciting HSUVs directly are gam-
bling with respect to a hypothetical treatment that may
result in perfect health or death (standard gamble, SG)
or trading-off part of future life for a shorter time in per-
fect health (time trade-off, TTO) [5]. A further, simpler
option is to use a visual analog scale (VAS), also known
as rating scale, which provides an immediate valuation
of the current (or a hypothetical) health state on a grad-
uated scale, usually ranging between 0 and 100. This
technique is generally considered to be methodologically
inferior to choice tasks such as SG and TTO, which in-
corporate some extra information about the individual
risk attitude [4]; VAS scores, indeed, are elicited in a
choice-less context, and thus do not required respon-
dents to make trade-offs within their utility function [6].
Moreover, the rating scales are well-known to present
measurement biases such as context bias, spacing-out
bias, and end-aversion bias [4, 7]. Additionally, there is
now consensus that health-related quality of life
(HRQoL) is a multi-dimensional concept, which includes
domains related to physical, mental, emotional, and
social functioning that are difficult to measure on a
single scale [8].
Direct measurement of health utility through SG or
TTO can be complicated and time-consuming and lead
to incomparable results across the studies due to
arbitrary health state descriptions (also called ‘vignettes’)
[9, 10]. Consequently, in recent years, HSUVs have been
increasingly estimated indirectly using multi-attribute
utility instruments (MAUIs). These tools are formed of a
generic HRQoL questionnaire and an accompanying
formula or set of weights (or “tariffs”) elicited from a
sample of the general population for converting re-
sponses into HSUVs; thus, the utility measure can be
considered as a preference-based evaluation of a given
health state described by the dimensions of the tool
[11, 12]. The National Institute for Health and Care
Excellence (NICE) and the European Network for
Health Technology Assessment (EUnetHTA) recom-
mend the EuroQol 5-dimension questionnaire (EQ-5D)
(https://euroqol.org) [13, 14]. Accordingly, the TTO
with a 10-year time horizon is the most frequently used
approach among the direct techniques, because of
greater comparability with the method used to develop
the EQ-5D scoring algorithm [15]. The other generic
MAUIs mostly adopted in the literature [11] are the
Health Utility Index (HUI mark 2, HUI2 or mark 3,
HUI3) [16], the Short Form-6-dimension (SF-6D) ques-
tionnaire derived from the 36-item Short Form Survey
(SF-36) (https://www.sheffield.ac.uk/scharr/sections/
heds/mvh/sf-6d), the 15D (www.15d-instrument.net),
the Quality of Wellbeing (QWB) index [17] and the As-
sessment of Quality of Life (AQoL) instruments [18].
In many situations, clinical studies neither administer
preference-based MAUIs nor elicit HSUVs directly, but
collect instead disease-specific HRQoL data or other
clinical measures that are not associated with a
preference-based scoring system; thus, QALY calculation
from these studies is not possible. As a second-best solu-
tion, “mapping” or “cross-walking” has been developed
to predict HSUVs from non-preference-based scores,
provided that a statistical relationship can be established
between the two instruments and, sometimes, allowing
for the mediating effect of demographic and clinical
characteristics [19].
This study focuses on HSUVs in head and neck cancer
(HNC). Patients with HNC often undergo several rounds
of treatment during which they experience acute toxicity
and other side effects, such as loss of verbal abilities, dif-
ficulties in swallowing, and considerable pain [20]. This
HRQoL impairment may continue long after treatment
through persistent functional deficits, physical disfigure-
ment, psychological distress, and recurrent disease.
There is an extensive HRQoL literature in HNC,
although mainly comprised of disease-specific, non-
preference based data unsuitable for cost-utility compar-
isons. Due to the paucity of HSUVs for some health
states in HNC, some previous cost-effectiveness analyses
[21, 22] relied on values calculated for other cancers
(such as breast or lung) to populate their models with
utility parameters. A systematic review published in
2006 [23] identified eight studies providing utility values
in HNC elicited through VAS, TTO or SG. Our study
extends the collection of utility values related to this
medical condition by systematically reviewing the studies
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published to date. This paper considers for inclusion
studies of any design in which utility values in HNC were:
 directly elicited using standard techniques such as
TTO or SG either in patient-based studies or in the
general population;
 calculated indirectly from patient’s responses to
generic MAUIs (e.g. EQ-5D) through a set of tool-
and country-specific preference weights;
 predicted from non-preference based HRQoL
instruments using mapping algorithms.
The Preferred Reporting Items for Systematic Reviews
and Meta-Analyses (PRISMA) statement [24] is not en-
tirely applicable to systematic reviews of HSUVs [25],
since the standard Population, Intervention, Comparator,
and Outcome (PICO) elements do not provide a useful
framework for identifying utility values for health states
that are not necessarily attached to a given intervention
[26]. Thus, in this study we follow the recommendations
provided by Papaioannou et al. [26]. The ultimate ob-
jective is to generate a database of HSUVs that might be
useful to populate future cost-utility studies of interven-
tions in HNC. In addition, we critically appraise the in-
cluded studies by highlighting a few elements that
should be considered when selecting utility parameters
for modeling.
Methods
A systematic literature search was carried out of the
PubMed, EMBASE and Cochrane Library databases for
studies published from 2000 until the end of 2016 using
a range of free-text terms in title/abstract (Fig. 1). Since
Medical Subject Headings (MeSH) terms provide little
coverage of HSUVs [25, 26], we identified a few relevant
free-text terms by referring to the published recommen-
dations [26] and recent analogous systematic reviews
[25, 27, 28]. Tool- (e.g. EQ-5D) and method-specific
(e.g. SG) terms were combined with vocabulary related
to HNC including the most frequent cancer sites; in
using free-text terms, we considered that some instru-
ments may be referred to or spelled in different ways.
We did not explicitly included VAS among the key-
words, due to the above-mentioned limitations in using
this tool for measuring utility. Other search strings were
used to identify cost-effectiveness and cost-utility studies
using HSUVs to calculate QALYs. We searched directly
utility weights in the Tufts Cost-Effectiveness Analysis
(CEA) Registry [29] and the University Sheffield School
of Health and Related Research Health Utilities Database
(ScHARRHUD) [30]. An additional search was carried
out of the Health Economics Research Centre (HERC)
database [31] to retrieve mapping studies deriving utility
values from non-preference based instruments in HNC.
We selected the relevant databases based on previous
recommendations [26] and systematic reviews on the
topic [32]. Web searches of grey literature were not per-
formed to avoid obtaining contents which are frequently
subject to changes and cannot be identified in a system-
atic manner.
All search results were extracted in an Excel spread-
sheet and duplicates removed. Titles and abstracts were
screened by two independent reviewers and records ex-
cluded if not meeting the inclusion criteria; full-text pa-
pers were retrieved in case of doubtful results. Articles
estimating HNC utility values using established methods
were included; studies using the VAS instrument were
not considered for inclusion, unless alongside other
valuation techniques. This choice is consistent with the
suggestion that VAS should be used as an introductory
task but not as a definitive method to elicit utility values
alone [33]. The included studies had to be published as
full-text with no time or language restrictions; confer-
ence abstracts, editorials, and reviews were not suitable
for inclusion. Studies were excluded if they did not re-
port original utility values in HNC; however, the bibliog-
raphy of studies referring to secondary sources for
HSUVs was checked to avoid missing any relevant publi-
cations. The authors resolved any disagreements by
discussion until consensus was reached.
The characteristics of the included studies were
extracted by the first reviewer (MM) using a form devel-
oped following previous studies [25–27], and subse-
quently crosschecked by the other author (JC).
Information collected included: study country, study de-
sign, sample size, valuation technique, administration
method, cancer subsite addressed, and clinical and
demographic characteristics of respondents. For each
Fig. 1 Free-text terms for electronic database searching
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HSUV, we recorded the number of respondents, the
point estimate (i.e. mean or median) and its measure of
variance (e.g. standard deviation); the same information
was collected for each study subgroup (or time point)
whenever applicable.
Although there are no agreed reporting standards for
HSUVs studies, the methodological quality of each in-
cluded study was evaluated through a set of generic cri-
teria as reported by the guidelines from Papaioannou et
al. [26]. Thereafter, one point was awarded to each of
the following criteria: (1) sample size ≥100; (2) descrip-
tion of respondent selection and recruitment; (3) de-
scription of inclusion/exclusion criteria; (4) response
rate ≥ 60% [34]; (5) reporting of the amount and reasons
of loss to follow-up (only for longitudinal studies); (6)
reporting of missing data pattern and methods to deal
with it; (7) appropriateness of measure (based on the au-
thors’ judgment). Lastly, the scores were summed for
each article to yield an overall quality score, ranging
from 0 to 7 where higher scores indicated higher quality
[35]. Any other problems arising from the studies
(criterion 8) were narratively discussed. Additionally, the
International Society for Pharmacoeconomics and
Outcomes Research (ISPOR) recently published a set of
recommendations for mapping studies [19] that were
used to evaluate the quality of mapping studies retrieved
by the systematic search.
Results
Study selection
The PRISMA diagram [24] for this literature search is pre-
sented in Fig. 2. In total, the search strategy identified
1048 articles: 1046 were retrieved by searching the online
databases (PubMed; EMBASE; The Cochrane Library;
CEA Registry; HERC database), and two by manually
searching the bibliography of model-based economic eval-
uations retrieved from the online search. No articles were
obtained from the ScHARRHUD database. After remov-
ing 743 duplicates, 305 records were scanned for title/ab-
stract and 221 were excluded in this first phase for a
variety of reasons reported in the chart. Subsequently, 84
full-text articles were retrieved and a further 56 records
were excluded for not complying with the inclusion/exclu-
sion criteria. Accordingly, 28 studies were definitively
included in the review.
Study characteristics
The 28 journal articles included in the review are catego-
rized into three groups: studies using direct elicitation
methods (n = 10), studies administering MAUIs (n = 13)
and studies deriving HSUVs using mapping (n = 3); two
studies [36, 37] adopted both direct methods and MAUIs.
The characteristics of the 25 studies using direct and in-
direct techniques (i.e. MAUIs) are listed in Table 1, while
Fig. 2 PRISMA flow chart
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Table 1 Studies estimating HSUVs in HNC using direct or indirect methods (n = 25)
Author
(year)
Country Study design Cancer
subsite(s)
Valuation
method
Mode of
administration
Sample size Response rate Participants (Mean) age;
% male
Aro
(2016) [56]
Finland Longitudinal All 15D Self-
completion
(by post)
214 72% Patients 63.0; 66%
Conway
(2012) [38]
Australia Cross-sectional Oropharynx SG 1-h group
session
99 84% Healthy subjects 43.0; 54%
de Almeida
(2014) [44]
US Cross-sectional Oropharynx SG; VAS Face-to-face
interview
59 NA Healthy subjects
(n = 50) and
experts (n = 9)
Healthy
subjects:
34.8; 42%.
Experts:
45.3; 89%
del Barco
Morillo
(2016) [47]
Spain Longitudinal All EQ-5D-3 L NA 40 NA Patients 61 (Median);
87%
Govers
(2016) [54]
Netherlands Cross-sectional Oral
cavity
EQ-5D-3 L Self-
completion
(by post)
181 62% Patients 64.4; ≥50%
Hamilton
(2016) [39]
UK Cross-sectional Larynx TTO Face-to-face
interview
114 NA Healthy subjects
(n = 51) and COPD
patients (n = 63)
67.3; 49%
Higgins
(2011) [58]
Canada Cross-sectional Larynx HUI3 Self-completion 30 NA Patients NA
Hollenbeak
(2001) [40]
US Cross-sectional All TTO NA 8 80% Patients NA
Jalukar
(1998) [41]
US Cross-sectional All TTO Self-
completion
(on site for
patients; by
email for
healthcare
professionals)
185 Patients: 78%;
healthcare
professionals:
42%;
students: NA
Patients (n = 49);
healthcare
professionals
(n = 50); s
tudents (n = 86)
Patients: 57.2;
71%
Healthcare
professionals:
40.1;
40%; students:
NA
Kent
(2015) [59]
US Cross-sectional Oral
cavity
and pharynx
SF-6D/
VR-6D
Mail or
telephone
580 62% Patients 67.7; 60%
Llewellyn-
Thomas
(1993) [45]
Canada Longitudinal Larynx TTO/VAS Interview 66 NA Patients NA; 86%
Loimu
(2015) [57]
Finland Longitudinal Pharynx,
larynx,
nasal cavity
15D Self-
completion:
on site (first
assessment);
by post
(afterwards)
64 76% Patients 61.6; 75%
Marcellusi
(2015) [36]
Italy Cross-sectional All TTO; EQ-
5D-3 L
Computer-guided 79 NA Patients 65.0; 78.5%
Noel
(2015) [37]
Canada Cross-sectional All SG; TTO;
VAS; EQ-
5D-5 L;
HUI3
Face-to-face
interview
100 79% Patients 61.0; 75%
Ouattassi
(2016) [48]
Morocco Cross-sectional All EQ-5D-3 L Self-
completion
120 NA Patients 57.0; 60%
Parrilla
(2015) [49]
Italy Longitudinal Larynx EQ-5D Self-
completion
30 NA Patients 68.7; 93%
Pickard
(2016) [52]
US Cross-sectional All EQ-5D-3 L Self-
completion
50 NA Patients 56.0; NA
Pottel
(2015) [55]
Belgium Longitudinal All EQ-5D-3 L Self-
completion
or interview
on site (first
assessment);
by post (afterwards)
81 81% Patients 72.0; 86%
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the three mapping studies are separately described in
Table 2.
Studies using direct or indirect methods
Among the studies using direct elicitation techniques,
SG alone was adopted in two cases [20, 38] and TTO
alone in five [39–43]. In four studies [37, 44–46], more
than one direct methodology (i.e. SG, TTO, VAS) was
adopted to derive utility values. The study by Noel et al.
[37] compared these direct techniques with MAUIs (i.e.
EQ-5D, HUI3), while a further study [36] used both
TTO and EQ-5D instruments.
In studies administering MAUIs, EQ-5D was the most
common (n = 11); five of these studies [36, 37, 47–49] did
not report which scoring algorithm was used, two studies
[50, 51] explicitly adopted the UK algorithm, another two
[52, 53] adopted the US one, one study [54] used the
Dutch tariff and another one [55] the Belgian one. More-
over, nine of the studies using EQ-5D [36, 47, 48, 50–55]
explicitly referred to the 3-level version (EQ-5D-3 L) and
one [37] to the newer 5-level one (EQ-5D-5 L); one study
[49] did not specify the instrument’s version adopted.
Additional generic, preference-based HRQoL tools re-
trieved by our search were 15D (n = 2), HUI3 (n = 2) and
Table 1 Studies estimating HSUVs in HNC using direct or indirect methods (n = 25) (Continued)
Ramaekers
(2011) [51]
Netherlands Cross-sectional All EQ-5D-3 L Self-completion 396 93% Patients 63.2; 70%
Ringash
(2000) [42]
Canada Cross-sectional Larynx TTO Face-to-face
interview
120 49% Patients 65; 83%
Rogers
(2006) [50]
UK Cross-sectional Oral cavity
and
oropharynx
EQ-5D-3 L Self-completion
(by post)
224 64% Patients 65; 58%
Szabo
(2012) [20]
Canada Cross-sectional Larynx, lip,
oral cavity,
oropharynx
SG Interview using
script and prop
101 95% Healthy subjects 47; 48%
Truong
(2016) [53]
US RCT Oropharynx,
hypopharynx,
larynx
EQ-5D-3 L Self-completion 818 87% Patients Arm CIS: 56.1;
86%.
Arm CET/CIS:
57.3; 89%
van der
Donk
(1995) [46]
Netherlands Cross-sectional Larynx TTO/SG/
VAS
Face-to-face
interview
39 NA Laryngeal cancer
patients (n = 10),
FOM cancer
patients (n = 10),
experts (n = 9),
healthy subjects
(n = 10)
Laryngeal
cancer
patients: 62;
FOM cancer
patients: 56;
experts: 43;
healthy
subjects: 36
Weiss
(1994) [43]
US Cross-sectional Pharynx,
larynx
TTO NA 3 NA Clinical experts NA
Abbreviations: CIS radiation-cisplatin without cetuximab, CET/CIS radiation-cisplatin with cetuximab, COPD chronic obstructive pulmonary disease,
EQ-5D-3 L EuroQol 5-dimension 3-Level, EQ-5D-5 L EuroQol 5-dimension 5-Level, FOM floor-of-the-mouth, HNC head and neck cancer, HSUV health state
utility value, HUI3 Health Utility Index Mark 3, NA not available, SF-6D Short Form-6-dimension, SG standard gamble, TTO time trade off, VAS visual
analogue scale, VR-6D Veterans RAND-6-dimension
Table 2 Mapping studies predicting HSUVs in HNC (n = 3)
Author
(year)
Country Mapping
technique
From
(tool 1)
To
(tool 2)
Sample’s
description
(algorithm)
Sample size
(algorithm)
Study ref.
(algorithm)
Sample’s description
(tool 1)
Sample size
(tool 1)
Study ref.
(tool 1)
Chan (2014) [60] Canada OLS UW QOL v4 EQ-5D-3 L Patients
treated
for HNC
89 (estimation);
48 (validation)
Parthan (2009) [61] UK Published
algorithm
EORTC QLQ-
C30
EQ-5D-3 L Patients
with liver
metastases
75 Krabbe
(2004) [63]
Patients with
locally advanced
inoperable HNC
358 Vermorken
(2007) [66]
Yong (2012) [62] Canada Published
algorithm
SF-36 HUI2 Various
patients
6921 Nichol
(2001) [64]
Patients with
early stage
nasopharyngeal
cancer
51 Pow
(2006) [65]
Abbreviations: EORTC QLQ-C30 European Organization for Research and Treatment of Cancer Quality of Life Core Questionnaire, EQ-5D-3 L EuroQol
5-dimension 3-Level, HNC head and neck cancer, HSUV health state utility value, HUI3 Health Utility Index Mark 3, OLS ordinary least square regression,
SF-36 36-Item Short Form Health Survey, UW QOL v4 University of Washington Quality of Life questionnaire, version 4
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SF-6D (n = 1); no studies used the QWB scale or the
AQoL-8D utility instrument.
The 25 articles reported on HNC utility-related studies
conducted in several European (Belgium, n = 1; Finland,
n = 2; Italy, n = 2; Netherlands, n = 3 Spain; n = 1 United
Kingdom, n = 2) and non-European countries
(Australia, n = 1; Canada, n = 5 Morocco, n = 1; United
States, n = 7). The great majority of the HSUVs came
from cross-sectional surveys (n = 18); the remaining ar-
ticles (n = 7) adopted a longitudinal design, including
five prospective cohort studies [45, 49, 55–57] and two
clinical trials [47, 53].
Sample sizes varied widely from 3 [43] to 818 [53],
with a mean of 152 respondents per study. The response
rate was between 49% [42] and 95% [20]. In most of the
studies (n = 18), the participants were HNC patients at
various stages of disease and treatment pathway; in two
studies [20, 38] healthy individuals from the general
population were surveyed through the SG techniques,
while in one case [43] the utility assessment was based
on a consultation with a panel of experienced physicians.
The remaining four studies [39, 41, 44, 46] retrieved util-
ity measures from multiple subjects (i.e. healthy people,
clinical experts, HNC patients and patients with other
medical conditions) and reported HSUVs from each
group separately.
In studies recruiting HNC patients, most were male
and the mean age was always above 55. Conversely, re-
sponders were generally younger and with a higher pro-
portion of females in studies surveying individuals from
the general population or clinical experts. The range of
cancer subsites addressed by each study was quite broad:
ten studies [36, 37, 40, 41, 47, 48, 51, 52, 55, 56] gener-
ally investigated utility in HNC without specifying any
cancer site, six [39, 42, 45, 46, 49, 58] were related to
laryngeal cancer, two [38, 44] addressed cancer in the
oropharynx, one [54] recruited patients affected by
cancer in the oral cavity and the remaining six [20, 43,
50, 53, 57, 59] focused on selected multiple sites (e.g.
oropharynx, hypopharynx, and larynx).
The most common way (n = 12 [41, 48–58]) of collect-
ing utility data was by self-completion of a written survey
(administered on site or by post/e-mail), followed by face-
to-face interviews (n = 6 [37, 39, 42, 44–46]); four studies
adopted different administration options including group
session (n = 1 [38]), telephone or mail interview (n = 1
[59]), interview using a script/prop (n = 1 [20]), and
computer-guided data collection (n = 1 [36]). The admin-
istration method was not specified in three cases [40, 43,
47]. When HSUVs were obtained from the patients, the
survey (or the interview) was usually scheduled during a
clinical appointment or a hospital admission; in longitu-
dinal studies [55, 57], surveys after the first were
frequently delivered by post to the patient’s home address.
Mapping studies
The three studies deriving HSUVs in HNC using a map-
ping technique are described in Table 2. Among them,
only one [60] developed an original mapping algorithm
using responses from HNC patients and was retrieved
from the HERC database. Ordinary Least Square (OLS)
regression was applied to establish a statistical relation-
ship between the University of Washington Quality of
Life questionnaire version 4 (UW QOL v4) and the EQ-
5D-3 L using a dataset of 89 patients treated for HNC.
Thereafter, the responses of an additional 48 patients
enrolled in the study were used as a validation database.
The other two studies [61, 62] were model-based
economic evaluations reporting HSUVs for several
HNC-related health states by applying previously
published algorithms [63, 64] to HRQoL data retrieved
from the literature [65, 66].
Overview of HSUVs
A total of 346 original HSUVs were retrieved from 27
studies included in the review (Additional file 1: Table S1),
since one study [41] reported results only graphically in
the article. The studies [37, 44, 46] providing the highest
number of HSUVs (i.e. over 40) either adopted multiple
techniques or interviewed several groups of respondents
that yielded different values for each health state. In other
cases [45, 49, 53, 55–57, 62], different HSUVs have been
collected by the same participants over the study time
points. HSUVs were reported as means in the great major-
ity of studies (n = 25), of which four [20, 38, 51, 53] also
reported the median; the remaining two studies [47, 55]
calculated a median value only. Among the measures of
variance, standard deviation was the most frequently
adopted (n = 12), followed by the min-max range (n = 7),
and the interquartile range (n = 5); several studies reported
more than one measure type. In some cases [39, 43, 46,
58, 62], no measures of variability were reported, thus
limiting the usefulness of the utility data.
Study quality assessment
The quality assessment of the 25 studies using direct or
indirect methods was based upon eight criteria, of which
seven were given a score (Table 3). In all studies, the in-
strument adopted to estimate HSUVs was considered
appropriate in relation with the participants enrolled.
Additionally, most studies (84%) reported a description
of the participants recruitment process, whilst only 56%
of them clearly stated the inclusion/exclusion criteria.
Information on missing data and techniques to deal with
them were reported by a limited number of studies
(24%). In half of the studies, the sample size was rather
small (<100) and response rate was either low (<60%) or
not reported. In reviewing these studies, we highlighted
a few additional issues (criterion 8 [26]) that should be
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considered when selecting sources to populate health
economic models with utility parameters. First, some of
the included studies are quite dated (published before
2000), thus describing health states that might not be
realistic nowadays because of emerging treatment mo-
dalities, improvements in treatment-related morbidity
and organ preservation techniques. Second, there might
be potential sources of bias in reporting HRQoL results
in clinical studies investigating one or more interven-
tions, although the number of comparative trials re-
trieved by our search was very limited. Third, in some
studies [36, 48, 59, 60], and especially those analyzing
HRQoL in multiple cancers including head and neck
[36, 59], patient’s characteristics (e.g. cancer stage/site,
treatment phase) are poorly reported, thus making it dif-
ficult to match the study’s HSUVs with the health states
described in a cost-effectiveness model. Lastly, the great
majority of studies are cross-sectional surveys, repre-
senting the quickest and cheapest method for gathering
HRQoL data; however, longitudinal data collections are
often more valuable since they facilitate capture of
changes in utility values as cancer progresses through
different phases.
With reference to mapping, we retrieved only one ori-
ginal algorithm [60] through the search, thus preventing
a comparative evaluation of studies. This study pre-
sented a four-variable model to predict EQ-5D-3 L util-
ities using OLS regression; coefficient values and error
terms were clearly reported and box-plot distributions of
actual and predicted utilities provided. However, the au-
thors did not justify the model choice in relation to the
observed EQ-5D distribution, nor any additional tests or
judgments made. The goodness-of-fit was presented as
R,2 mean absolute error (MAE) and root mean squared
error (RMSE), which are considered of limited value in
the mapping field. No demographic or clinical variables
were included as covariates, which was recognized as a
study limitation by the same authors. Moreover, when
the sample size is small (as it was in this study), the most
recent guidelines do not recommend splitting it for em-
pirical validation [19].
Discussion
This study reviews systematically published studies
reporting HSUVs in HNC. Compared to a previous re-
view [23], many more studies have been identified, most
of which use the EQ-5D and were published from 2011
onwards. Overall, this review shows that HNC patients
suffer from substantial HRQoL impairment over the
different disease phases. However, there is a lack of
research into the HRQoL in the recurrent and/or meta-
static health states, with only one study [47] reporting a
median EQ-5D utility value (i.e. 0.7) from the patients,
which is less useful for the purposes of economic
evaluation that focuses on mean costs and effects. An-
other study [44] elicits values for a range of recurrent
disease states from healthy subjects and clinical experts
using SG and VAS and obtains extremely heterogeneous
results across the types of participants and methods.
The same paucity of HSUVs was observed for
treatment-related complications, which are addressed by
three studies [20, 44, 45] only, possibly because of the
infrequency of some of these events that restricts the
data from patients in that health state.
Differences in utilities were found across studies even
in the pre-treatment state. The choice of baseline utility
is particularly relevant because it affects the incremental
gain achievable by different therapeutic options [13],
thus potentially biasing the estimated cost-effectiveness.
The two Finnish studies [56, 57] using the 15D yielded
higher utility values in patients shortly after diagnosis
than those using the EQ-5D [53, 54]. This phenomenon
has previously been observed in studies addressing other
medical conditions [32, 67, 68]. There are many possible
explanations for these discrepancies: different number of
dimensions, the EQ-5D has generally been valued using
TTO rather than VAS [69], the preference weights have
come from different populations (a Finnish value set is
usually adopted for 15D) [67], and the EQ-5D, unlike
the 15D, can take negative values [69, 70]. The partici-
pants’ characteristics might have also affected study re-
sults. For example, a study [55] addressing HRQoL in
patients aged ≥65 years with HNC consistently provided
lower HSUVs than other studies in either the pre-
treatment, treatment, and follow-up phases, probably
because of comorbidities and functional impairments
usually affecting elderly people independently from
cancer. Moreover, the use of different scoring algorithms
may have contributed to variation in HSUVs in studies
administering the EQ-5D.
Heterogeneity in utility values was particularly evident
in the studies applying more than one technique to
evaluate the same health state. Among them, in a study
reporting HSUVs for different treatments, treatment-
related complications, and remission/recurrence states
in oropharyngeal cancer [44], the values obtained using
a VAS scale were consistently lower that for the SG. In
the study by Marcellusi et al. [36], patients in follow-up
after treatment for HNC reported lower utility values
when performing the TTO task than when responding
to the EQ-5D questionnaire. Another study [37] com-
pared five different (direct and indirect) methods to re-
trieve HSUVs from patients experiencing a similar
health state (i.e. three months after completion of treat-
ments and no evidence of recurrent disease). Unlike
Marcellusi et al. [36], the method yielding the highest
utility value in the overall sample (n = 100) was TTO
(0.94), followed by SG (0.91), EQ-5D (0.82), VAS (0.76)
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and HUI3 (0.75). That VAS scores are consistently lower
than SG scores is well-known in the literature; in 2001,
Torrance et al. [33], after reviewing several studies, con-
cluded that the relationship between the two instru-
ments can be represented by a concave curve passing
through 0 and 1. Moreover, the indirect methods involv-
ing MAUIs have been shown to yield systematically
lower utility values than the direct ones in a wide range
of diseases [71] for a variety of reasons. First, in MAUIs
participants are not asked to consider their health status
relative to death and thus, there is no disincentive in
reporting more severe health problems [72]. Second, re-
spondents are forced to describe their complex medical
conditions through a limited number of attributes, thus
ignoring any positive feelings that would boost utility
values. Third, it is likely that the general population used
to obtain tariffs for MAUIs make a different trade-off
between a given health state and death because they
tend to be younger and healthier. Finally, the vignettes
described in direct valuation tasks are usually more de-
tailed than the MAUI health states [71]. In studies com-
paring alternative MAUIs, EQ-5D has been shown to
provide higher utilities values compared to HUI2 and
HUI3, which in turn yield higher values than SF-6D. As
for the differences between EQ-5D and 15D, potential
explanations are likely to be found in descriptive sys-
tems, preference measurement, source of community
preferences, and scoring methods [73].
In addition, studies can be classified by the type of re-
sponders who valued the health states, either patients or
healthy subjects. In the literature, some argue that pa-
tients are best placed to value the relevant health states,
while others advocate valuation by healthy people who
will not directly benefit from a new treatment but, in
tax-based systems, will bear its cost. The latter claim
that this will provide an unbiased estimate of the hypo-
thetical health states [7, 74] and more consistency across
appraisal of very different interventions. The review by
Komatsuzaki et al. [23] showed that patients usually re-
ported lower utilities than physicians and healthy people
for health states associated to HNC. In this review, only
a few studies recruited participants from the general
population, thus limiting the number of utilities compar-
isons across different types of responders. One study
[46] confirms the conclusions reached by the previous
review [23], whilst others [41, 44] found healthy subjects
consistently providing lower utility estimates compared
to patients and healthcare professionals.
This study facilitates the identification of HSUVs for
use in future HNC economic evaluations. The number
of retrieved studies was quite large, with almost 350 dis-
tinct HSUVs collected from them. Most of the utility
values were collected during the treatment phase or
shortly after the completion of treatment, whilst limited
evidence is available for the health-related utility assess-
ment in HNC recurrent and end-of-life states. Due to
the variety of health state definitions and valuation tech-
niques across the studies, we were not able to perform a
quantitative synthesis of the results [3]. Moreover, unlike
cost-effectiveness studies where structured guidelines
exist to support authors and reviewers in assessing their
quality [75, 76], recommendations for valuation studies
specifically aimed at measuring HSUVs are more frag-
mented or method-specific [10]. In this review, the as-
sessment of study quality was based on a set of generic
recommendations elaborated by a previous study [26]
and arbitrarily modified to allow a quantitative scoring
of the studies adopting direct and indirect techniques to
estimate HSUVs; for mapping studies, we relied instead
on recent ISPOR guidelines [19].
Although there is no universally accepted theoretical
basis for choosing direct or indirect methods [71], the
use of the EQ-5D, is favored by several agencies includ-
ing NICE, the Canadian Agency for Drugs and Tech-
nologies in Health and the French National Authority
for Health [3]. In a recent position statement [77], NICE
recommends the use of EQ-5D-3 L for base-case ana-
lyses, or mapping EQ-5D-5 L responses onto the 3 L
valuation set, to derive HSUVs, since further research is
needed to explore the impact of adopting the EQ-5D-
5 L valuation set on technology appraisal. In model-
based cost-effectiveness studies, where there is a choice
of HSUVs, those using the value set of the jurisdiction
for which a decision is being made are usually preferred.
Moreover, HSUVs should be collected from studies en-
rolling patients with demographic and clinical character-
istics that mostly resemble those of potential recipients
of the intervention under investigation in the model.
Until now, studies relying on direct techniques represent
the only available source to retrieve HSUVs for recurrent
disease, palliative states, or treatment-related complica-
tions in HNC. Although considered as qualitatively in-
ferior to MAUIs [3], these methods can provide values
for cost-effectiveness analyses where the ‘vignettes’ pre-
sented in the choice task fit with the health states ad-
dressed in the model. Finally, in the absence of
preference-based data, mapping from disease-specific in-
struments to generic MAUIs may represent a valuable
alternative [74]; however, the only algorithm published
to date in HNC [60] does not map from one of the
HRQoL tools most frequently adopted in cancer studies,
such as the European Organization for Research and
Treatment of Cancer 30-item Quality of Life Core
Questionnaire (EORTC QLQ-C30 [78]) and the
Functional Assessment of Cancer Therapy - General
(FACT-G [79]). Greater availability of mapping functions
would facilitate the comparison of treatments using
HRQoL data from many randomized controlled trials
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that only collected disease-specific health status infor-
mation. Overall, the use of different techniques for util-
ity elicitation might have substantial implications in
cost-utility analyses; for example, it has been shown [71]
that MAUIs, compared to direct valuation, tend to favor
non-lifesaving treatments over interventions preventing
or delaying death. Thus, regulatory bodies should avoid
a mixture of methods in their decision processes to
avoid a biased allocation of healthcare resources. More-
over, health economic modelers are always recom-
mended to extensively test the uncertainty around the
utility parameters in sensitivity analyses [71].
Conclusions
This study improves understanding of preference-based
HRQoL measurement in HNC by systematically review-
ing and critically evaluating studies that estimated
HSUVs in this cancer setting. Utility values are an essen-
tial parameter but also a major source of uncertainty in
model-based economic evaluations, where it is common
to select them from a single study based on clinical con-
siderations [3, 28]. Further studies on the health-related
utility assessment from HNC patients using MAUIs in
recurrent and terminal states are encouraged. Additional
research on mapping algorithms to convert disease-
specific HRQoL results onto preference-based HSUVs
would be of value in this cancer population. Overall, the
methods used to identify utility values within a growing
body of HRQoL literature should be increasingly system-
atic and justified in future studies.
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